Press release
Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report
Report Table of Contents
1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview
4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
6. Global Malignant Melanoma Clinical Pipeline By Company & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Registered
7. Global Malignant Melanoma Marketed Drugs Clinical Insight
7.1 Talimogene Laherparepvec (IMLYGIC)
7.2 Nivolumab (Opdivo)
7.3 Temozolomide (Temodal & Temodar)
7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegintron, Pegtron & ViraferonPeg )
7.5 Pembrolizumab (Keytruda )
7.6 Vemurafenib
7.7 Ipilimumab (Yervoy)
7.8 Cobimetinib (Cotellic)
7.9 Trametinib (Mekinist)
7.10 Tc 99m Tilmanocept (Lymphoseek)
7.11 Dabrafenib (Tafinlar)
7.12 Aldesleukin (Chiron IL-2 & Proleukin)
7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)
7.14 Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)
7.15 Melanoma Vaccine - AVAX Technologies (MVax)
7.16 Interferon alpha - Swedish Orphan Biovitrim (Multiferon)
7.17 Interferon alpha-2b - Beijing Kawin Technology
7.18 Virulizin (Virulizin)
7.19 Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)
7.20 Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/ Response Genetics (THxID-BRAF)
7.21 Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)
7.22 Technetium Tc 99m Sulfur Colloid Injection – Pharmalucence
7.23 Interferon alpha-2a (Roferon-A)
7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
7.25 Melanoma Vaccine – GlaxoSmithKline (Melacine)
8. Competitve Landscape
8.1 AB Science
8.2 Celgene Corporation (Abraxis BioScience)
8.3 Array BioPharma
8.4 AVAX Technologies
8.5 Biogen Idec
8.6 BioVex
8.7 Bristol-Myers Squibb
8.8 Enzon Pharmaceuticals
8.9 Eisai Co
8.10 Exelixis
8.11 GlaxoSmithKline
8.12 Lorus Therapeutics (Aptose Bioscience)
8.13 Medarex
8.14 Merck
8.15 Navidea Biopharmaceuticals
8.16 Novartis
8.17 Ono Pharmaceutical
8.18 Onyx Pharmaceuticals
8.19 Pfizer
8.20 Pharmalucence (Sun Pharmaceutical)
8.21 Plexxikon
8.22 QIAGEN
8.23 Roche
8.24 Reliance Life Sciences
8.25 Servier
8.26 TC BioPharm
8.27 Viragen
Download Report: https://www.kuickresearch.com/report-Global-Malignant-Melanoma-Drug-Market-&-Clinical-Pipeline-Insight.php
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.
Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Melanoma Drug Market Malignant Melanoma Clinical Pipeline Report here
News-ID: 618914 • Views: 282
More Releases from Kuick Resarch
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights:
* NSCLC Targeting Lumakras Market Opportunity (US$ Million)
* Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million)
* Pharmacokinetics of Lumakras (Sotorasib)
* Dosage, Patent and Price Analysis
* Lumakras Ongoing Clinical Trials
* Global KRAS Protein Inhibitors Clinical Trials
Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase
The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management…
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights:
* Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026
* Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug
* Dosage, Price and Sales Analysis of Tazverik
* Tazverik Sales Opportunity > US$ 900 Million by 2026
* Tazverik Sales Forecast 2021 Till 2026
* EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase
* EZH2 Inhibitor in Clinical Trials: 7 Drugs
Download…
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights:
* Global Bispecific Antibody Market Opportunity: > US$ 20 Billion
* Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021)
* Approved Bispecific Antibodies In Market: 4 Antibodies
* Detailed Market Sales and Trends Insight Till 2028
* Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022
* Global and Regional Market Analysis
* Approved Drug Sales…
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights:
* Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026
* Role of FGFR Inhibitors in Cancer Therapy
* Global FGFR Market Assessment (US$) by Region and Cancer Type
Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq)
* Dosage and Drug Price Insight on Approved FGFR Inhibitors
* Comprehensive Clinical Trials Insight…
More Releases for Melanoma
Global Drugs for Melanoma Market Insights, Forecast
Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the malignant tumor. Mainly there are three general categories of melanoma as Cutaneous, mucosal and ocular. Cutaneous melanoma is melanoma of the…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
Melanoma Cancer Diagnostics Market: 7 Key Takeaways
According to a latest market research by fast-growing market research and consulting firm, the global melanoma cancer diagnostics market is poised to grow at over 7% CAGR and surpass US$ 853.5 million in revenues by 2022. Fact.MR’s report forecasts that North America and Europe will remain the most lucrative markets for melanoma cancer diagnostics market globally. Key takeaways from Fact.MR’s report are,
Request Free Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=57
• The U.S. melanoma cancer…
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in…
Melanoma Treatment Market – Global Industry Insights, 2025
Melanoma is a type of skin cancer that develops from the pigment cells known as melanocytes. It is caused due to high exposure to ultraviolet rays, which leads to sunburn, especially at high altitudes. Melanoma is categorized into three: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye. However, early detection of melanoma helps in…
Global Melanoma Therapeutics Sales Market Report 2017
This report studies sales (consumption) of Melanoma Therapeutics in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
BMS
Merck
Roche
AB Science
Amgen
Bayer
Celgene
Daiichi Sankyo
Eisai
GSK
Pfizer
Vical
Market Segment by Regions, this report splits Global into several key Regions, with sales (consumption), revenue, market share and growth rate of Melanoma Therapeutics in these regions, from 2011…
